HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Clinical Trial: Oral Ixazomib Maintenance for Non-Transplant Myeloma Patients
Posted: Feb 03, 2017
Clinical Trial: Oral Ixazomib Maintenance for Non-Transplant Myeloma Patients image

Ixazomib (Ninlaro) is an oral proteasome inhibitor approved in late 2015. It is now being used in a wide variety of treatment combinations and is also being evaluated as maintenance therapy. For patients who have received prior treatment and achieved some sort of major response (complete response, very good partial response or partial response), investigators are comparing ixazomib maintenance vs. no maintenance. The study will help investigators understand the impact of ixazomib as maintenance therapy and how it impacts progression free survival compared to no maintenance therapy. The study is open at 6 myeloma academic centers and is only for patients who have NOT undergone a stem cell transplant. To learn more, click the button below: Ixaxomib Maintenance Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube